Abstract
Bone remodelling is a tightly regulated process which occurs throughout adult life. The process consists of two main steps: bone resorption and bone formation phase. During these two phases, several breakdown products of bone matrix including C-terminal or N-terminal telopeptide of type 1 collagen (CTX, NTX) and collagen crosslinks (deoxypyridinoline, pyridinoline) as well as components involved in bone formation such as collagen type 1 propeptides, osteocalcin or enzymes (bone-specific alkaline phosphatase), are released in the circulation. These products can be measured and used clinically as biochemical markers to assess bone turnover rate. They provide a useful and non-invasive tool in the investigation and follow-up of patients with post-menopausal osteoporosis and other skeletal disorders. However, their variability presents a problem to their establishment in routine practice. Identifying the factors which contribute to this variability, the degree of variability and taking steps to minimise these such as standardisation of the assays and timing of sample, as well as the derivation of well-defined reference ranges, would improve the clinical utility of these bone markers in individual patients. The clinical uses of the biochemical markers of bone turnover are reviewed. Their role in the prediction of fracture risk and the assessment of treatment response in post-menopausal osteoporosis is described. The potential use of the markers in metastatic bone disease is also discussed.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ali SM, Derners LM, Leitzel K et al (2004) Baseline serum NTX levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15(3):455–459
Aoshima H, Kushida K, Takahashi M et al (1998) Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22:73–78
Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258
Bauer DC, Garnero P, Hochberg HC et al (2006) Pretreatment levels of bone turnover and antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299
Bjarnason NH, Sarkar S, Duang T et al (2001) Six- and twelve-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in post-menopausal osteoporosis. Osteoporos Int 12:922–930
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomised trial. JAMA 296:2927–2938
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis. N Engl J Med 356:1809–1822
Blumsohn A, Hannon RA, Eastell R (1995) Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 41:318–319
Bonde M, Garnero P, Fledelius C et al (1997) Measurement of bone degradation products in serum using antibodies reactive with an isomerised form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 12:1028–1034
Chapuy MC, Schott AM, Garnero P et al (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. Epidos Study Group. J Clin Endocrinol Metab 81:1129–1133
Charles P, Poser JW, Mosekilde L et al (1985) Estimation of bone turnover evaluated by 47Ca-kinetics. J Clin Invest 76:2254–2258
Chen P, Satterwhite JH, Licata AB et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970
Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al (2000) Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511
Claudon A, Vergnaud P, Valverde C et al (2008) New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 54(9):1554–1563
Cloos PAC, Fledelius C (2000) Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J 345:473–480
Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with anti-resorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin Endocrinol Metab 89:1117–1123
Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–639
Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with anti-resorptive drugs. Osteoporos Int 11(Suppl 6):S66–S76
Delmas PD, Eastell R, Garnero P et al (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11(Suppl 6):S2–S17
Delmas PD, Recker RR, Chestnut CH et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk; results from the BONE study. Osteoporos Int 15:792–798
Delmas PD, Vrijens B, Eastell R et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of post-menopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304
Diaz Diego EM, Guerrero R, de la Piedra C (1994) Six osteocalcin assays compared. Clin Chem 40:2071–2077
Dobnig H, Sipos A, Jiang Y (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90(7):3970–3977
Ducy P, Desbois C, Boyce B et al (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382:448–452
Eastell R, Delmas PD, Hodgson SF et al (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics and biochemical markers. J Clin Endocrinol Metab 67:741–748
Eastell R, Barton I, Hannon RA et al (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with Risedronate. J Bone Miner Res 18:1051–1056
Eastell R, Hannon RA, Cuzick J et al (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res 21:1215–1223
Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26(3):530–537
Emerton KB, Hu B, Woo AA et al (2010) Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 46(3):577–583
Eriksen EF, Charles P, Melson F et al (1993) Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8:127–132
Eriksen EF, Eghbali-fatourechi GZ, Khosla S (2007) Remodelling and vascular spaces in bone. J Bone Miner Res 22(1):1–6
Eyre DR, Paz MA, Gallop PM (1984) Cross-linking in collagen and elastin. Annu Rev Biochem 53:717–748
Fatayerji D, Eastell R (1999) Age-related changes in bone turnover in men. J Bone Miner Res 14:1203–1210
Fledelius C, Johnsen AH, Cloos PAC et al (1997) Characterization of urinary degradation products derived from type I collagen: identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha 1) region. J Biol Chem 272:9755–9763
Garnero P (2000) Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11(Suppl 6):S55–S65
Garnero P, Sornay-Rendu E, Delmas PD (1995) Decreased bone turnover in oral contraceptive users. Bone 16:499–503
Garnero P, Hansherr CMC et al (1996) Markers of bone resorption predict hip fracture in elderly women. The EPIDOS prospective study. J Bone Miner Res II:1531–1538
Garnero P, Fledelius C, Gineyts E et al (1997) Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget’s disease of bone. J Bone Miner Res 12:1407–1415
Garnero P, Sorney-Rendu E, Duboeuf F et al (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY Study. J Bone Miner Res 14:1614–1621
Garnero P, Borel O, Delmas PD 2001 A fully automated serum assay for C-terminal cross-linking telopeptide of type 1 collagen in osteoporosis. Clin Chem 47(4) : 694–702
Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of fully automated serum assay for total N-terminal propeptide of type 1 collagen in post-menopausal osteoporosis. Clin Chem 54(1):188–196
Glorieux FH (2008) Osteogenesis imperfecta. Best pract Res Clin Rheumatol 22(1):85–100
Glover SJ, Garnero P, Naylor K et al (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630
Golub EE (1996) Enzymes in mineralizing systems: state of the art. Connect Tissue Res 35:183–188
Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover to predict the long term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431–1438
Gundberg CM (2003) Matrix proteins. Osteoporos Int 14(Suppl 5):S37–S42
Gundberg CM, Markowitz ME, Mizruchi M et al (1985) Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab 60:736–739
Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11(Suppl 6):S30–S44
Hannon RA, Clowes JA, Eagleton AC et al (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187–194
Hansen MA, Overgaard K, Riis BJ et al (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303:961–964
Hanson DA, Weis MA, Bollen AM (1992) A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251–1258
Hatoum HT, Lin SJ, Smith MR et al (2008) Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a national medical claims database. Cancer 113(6):1438–1445
Hauge EM, Qresel D, Eriksen EF et al (2001) Cancellous bone remodelling occurs in specialised compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16(9):1575–1582
Hauschka PV, Liam JB, Cole DE et al (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047
Hayman AR, Bune AJ, Bradley JR et al (2000) Osteoclastic tartrate-resistant acid phosphatase (Acp5): its localization to dendritic cells and diverse murine tissues. J Histochem Cytochem 48:219–228
Hochberg MC, Greenspan S, Wasnich RD et al (2002) Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592
Kaddam IM, Iqbal SJ, Holland S et al (1994) Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline: creatinine ratio in patients with Paget’s disease of bone. Ann Clin Biochem 31:327–330
Kamel S, Brazier M, Neri V (1995) Multiple molecular forms of pyridinoline crosslinks excreted in human urines evaluated by chromatographic (HPLC) and immunoassay (ELISA) methods. J Bone Miner Res 10:1385–1392
Kearns AE, Khosla S, Kosteniuk PJ (2008) Receptor activator of nuclear factor-κB ligand and osteoprotegerin regulation of bone remodelling in health and disease. Endocr Rev 29:155–192
Kenn RW, Nguyen T, Sobnack R et al (1996) Can biochemical markers predict bone loss at the hip and spine? A 4-year prospective study of 141 early postmenopausal women. Osteoporos Int 6:399–406
Khosla S, Atkinson EJ, Melton LJ III et al (1997) Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 82:1522–1527
Khosla S, Burr D, Canley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491
Lam KW, Siemens M, Sun T et al (1982) Enzyme immunoassay for tartrate-resistant acid phosphatase. Clin Chem 28:467–470
Lee NK, Sowa H, Hinoi E et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469
Lewis LL, Shaver JF, Woods NF et al (2000) Bone resorption levels by age and menopausal status in 5157 women. Menopause 7:42–52
Linkhart SG, Linkhart TA, Taylor AK et al (1993) Synthetic peptide-based immunoassay for amino-terminal propeptide of type 1 procollagen: application for evaluation of bone formation. Clin Chem 39:2254–2258
Lipton A, Cook RJ, Major P et al (2007) Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12:1035–1043
Lipton A, Cook R, Saad F et al (2008) Normalisation of bone markers is associated with improved survival in patients with bone metastases from solid tumours and elevated bone resorption receiving zoledronic acid. Cancer 113(1):193–201
Luukinen H, Kakonen SM, Pettersson K et al (2000) Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res 15:2473–2478
Marcus R, Holloway L, Wells B et al (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J Bone Miner Res 14:1583–1595
Martin TJ, Seeman E (2008) Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab 22(5):701–722
Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 65:2397–2410
Meier DE, Luckey MM, Wallenstein S et al (1992) Racial differences in pre- and postmenopausal bone homeostasis: association with bone density. J Bone Miner Res 7:1181–1189
Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 350:459–468
Nakanishi M, Yoh K, Uchida K et al (1999) Clinical usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase activity in evaluating bone turnover. J Bone Miner Metab 17:125–130
Naylor KE, Iqbal P, Fledelius C et al (2000) The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 15:129–137
Nielsen HK, Brixen K, Bouillon R et al (1990) Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 70:1431–1437
Parfitt AM (2002) Targeted and non-targeted bone remodelling: relationship to basic multicellular unit origination and progression. Bone 30(1):5–7
Pedersen BJ, Schlemmer A, Rosenquist C et al (1995) Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Osteoporos Int 5:472–477
Perrien DS, Achenbach SJ, Bledsoe SE et al (2006) Bone turnover across the menopause transition: correlation with inhibins and FSH. J Clin Endocrinol Metab 91:1848–1854
Plebani M, Bernardi D, Meneghetta MF et al (2000) Biological variability in assessing the clinical value of biochemical markers of bone turnover. Clin Chem Acta 299:77–86
Pratt JH, Manatunga AK, Peacock M (1996) A comparison of the urinary excretion of bone resorptive products in white and black children. J Lab Clin Med 127:67–70
Price PA (1987) Vitamin K-dependent proteins. In: Cohn DV (ed) Calcium regulation and bone metabolism: basic and clinical aspects. Elsevier Science, Amsterdam, pp 419–425
Ravn P, Clemmesen B, Christiansen C (1999a) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women: Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244
Ravn P, Hosking D, Thompson D et al (1999b) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early post-menopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368
Register JY, Gieschke R (2006) Clinical utility of a pharmaco-statistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 7:827–836
Robbins SP, Woitge H, Hesley R, Ju J et al (1994) Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643–1649
Rodan G, Reszka A, Golub E et al (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291–1300
Rosen CJ, Hochberg MC, Bonnick SL et al (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 3 mg in women with postmenopausal osteoporosis: a randomised double-blind study. J Bone Miner Res 20:141–151
Sambrook PN, Chen CJ, March L et al (2006) High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21(4):549–555
Schousboe JT, Bauer DC, Nyman JA et al (2007) Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 18:201–210
Seibel MJ (2000) Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 11(Suppl 6):S518–S529
Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122
Seibel MJ, Naganathan V, Barton I et al (2004) Relationship between pre-treatment bone resorption and vertebral fracture incidence in post-menopausal osteoporotic women treated with risedronate. J Bone Miner Res 19:323–329
Stepan JJ (2000) Prediction of bone loss in postmenopausal women. Osteoporos Int 11(Suppl 6):S45–S54
Takahashi M, Kawana K, Nagano A (2002) Biological variability of biochemical markers of bone turnover in healthy woman. Endocr Res 28:257–264
Tamura Y, Araki A, Chiba Y et al (2007) Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab 25:226–231
Taylor AK, Linkhart S, Mohan S (1990) Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 70:467–472
Theoleyre S, Wittrant Y, Tat SK et al (2004) The molecular triad OPG/RANK/RANKL involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev 15:457–475
Van Daele PLA, Seibel MJ, Burger H et al (1996) Case–control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam Study. BMJ 312:482–483
Weaver CM, Peacock M, Martin BR et al (1997) Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy volunteers. J Bone Miner Res 12(10):1714–1720
Whyte MP (2010) Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci 1192(1):190–200
Wichers M, Schmidt E, Bidlingmaier F et al (1999) Diurnal rhythm of crosslaps in human serum. Clin Chem 45:1858–1860
Woitge HW, Seibel MJ, Ziegler R (1996) Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem 42(11):1796–1804
Yamaga A, Taga M, Minaguchi H et al (1996) Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium: a longitudinal study. J Clin Endocrinol Metab 81:752–756
Young MF (2003) Bone matrix proteins: their function, regulation and relationship to osteoporosis. Osteoporos Int 14(Suppl 3):S35–S42
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hampson, G. (2012). Biochemical Markers in Bone Diseases. In: Fogelman, I., Gnanasegaran, G., van der Wall, H. (eds) Radionuclide and Hybrid Bone Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02400-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-02400-9_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-02399-6
Online ISBN: 978-3-642-02400-9
eBook Packages: MedicineMedicine (R0)